Sonoma Pharmaceuticals posts 60% revenue rise, first positive EBITDA

Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) reported total revenues of $6.4 million for its fiscal first quarter ended June 30, 2026, a 60% increase from $4.0 million in the same period a year earlier, according to a company press release.

U.S. revenue rose 141%, or $1.4 million, driven by over-the-counter product sales and growth from new and existing distributors. European revenue increased 34%, or $0.5 million, attributed to higher demand and favorable exchange rates.

Gross profit reached $2.6 million, or 40% of revenue, compared to $1.5 million, or 36%, in the prior-year quarter. Total operating expenses were $2.6 million in both periods. The company reported a net loss of $330,000, down from a net loss of $1.2 million a year earlier. Net loss per share was $0.09, compared to $0.76 in the prior-year quarter.

On a non-GAAP basis, the company reported an adjusted EBITDA gain of $50,000 for the quarter, compared to an adjusted EBITDA loss of $1.0 million in the same period last year. The company described this as its first positive adjusted EBITDA result.

Cash and cash equivalents stood at $5.3 million as of June 30, 2026, up from $2.4 million as of March 31, 2026.

In June 2026, Sonoma received a 510(k) clearance from the U.S. Food and Drug Administration for its Microdacyn Wound Irrigation Solution, covering expanded claims, multiple-use clearance, and additional packaging configurations. The company also added new distributors in Taiwan, Vietnam, and the United States since the start of fiscal year 2027.

You May Also Be Interested In

• Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
• Jefferies Downgrades Xior Student Housing NV (XIOR:BB) to Hold
• Goldman Sachs Downgrades Schindler Holding AG (SCHN:SW) (SHLAF) to Sell